Greystone Research Associates is pleased to announce the publication of a new market study. Injectable Drug Delivery to 2016: Drugs, Devices, Therapies, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the drug delivery sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injectable drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
The past decade has seen a dramatic shift in terms of the types of approved injectable drugs, the diseases they target, and the devices used to deliver them. This shift has fostered change on several levels of the healthcare sector. The injectable drug segment has seen a marked increase in the level of drug/device integration, as prefilled syringes and specialized injection devices proliferate in response to safety and economic challenges posed by recombinant protein drugs, while administration of injectables has moved increasingly from practitioner offices and healthcare facilities to patient homes. This report examines the key therapeutic, product, market and regulatory factors for injectable drugs across ten major disease and therapeutic classes, providing essential insight and forecasts into the implications of this evolving landscape.
Note: The Table of Contents has Been Edited for Brevity. For a Completed Version, Please Request a Free Sample.
Browse more Drug Delivery System Market Research Reports